Abstract
There are over 10 million hepatitis C virus (HCV)-infected patients in Pakistan. For these patients, a combination of interferon with ribavirin is the most economical and easily available treatment. Single-nucleotide polymorphisms in interleukin genes have been reported to be associated with the pathogenesis and clearance of HCV, and sustained virologic response (SVR). An interleukin 28B (IL28B) gene polymorphism has been shown to modify treatment outcomes, but the effects of interleukin 10 (IL10) polymorphisms have not been previously assessed in the Pakistani population. The present study was conducted with 302 subjects categorized into two groups: 100 healthy volunteers (Group I) and 202 patients with chronic HCV (Group II). Patients within Group II were further divided into two subgroups according to therapeutic response: SVR (responders = 132) and NR (non-responders/relapsers = 70). IL28B (rs8099917, rs12979860) and IL10 (rs1800872, rs1800871, rs1800896) gene polymorphisms were studied in all subjects. A significant difference in the distribution of IL28B rs12979860C/T genotypes between the two groups (p<0.05) was observed, while of the three IL10 polymorphisms, a significant difference was only shown for rs1800896 A/G. Haplotype analysis (IL28B and IL10) showed a significant association of TTGTC and TTGTA when comparing the groups. There was a strong association of the favorable alleles rs8099917T and rs12979860C in the SVR group as compared with the NR group (p<0.05), and rs1800896 also showed an association with the SVR group as compared to the NR group (p<0.004). Haplotype analysis showed significant associations when comparing the SVR and NR subgroups, i.e. TCATC (p=0.009), TTGTA (p=0.005), TCATA (p<0.0005), TCACA (p=0.002), GTGCC (p=0.002) and TCGTC (p=0.005). IL28B (rs8099917 and rs12979860) and IL10 (rs1800896) polymorphisms alone, or in combination, are good predictors of therapeutic response in HCV-3a patients.
Similar content being viewed by others
References:
Abdelraheem WM, Hassuna NA, Abuloyoun SM, Abdel Ghany HM, Rizk HA, Abdelwahab SF (2016) Interleukin-10.rs1800896 and Interleukin-18.rs1946518 gene polymorphisms could not predict the outcome of hepatitis C virus infection in Egyptian patients treated with pegylated interferon plus ribavirin. Arch Virol 161:2473–2480
Afzal MS, Tahir S, Salman A, Baig TA, Shafi T, Zaidi NU, Qadri I (2011) Analysis of interleukin-10 gene polymorphisms and hepatitis C susceptibility in Pakistan. J Infect Dev Ctries 5:473–479
Afzal MS, Anjum S, Zaidi NU (2013) Effect of functional interleukin-10 polymorphism on pegylated interferon-alpha plus ribavirin therapy response in chronic hepatitis c virus patients infected with 3a genotype in Pakistani population. Hepat Mon 13:e10274
Alavian SM, Tabatabaei SV, Keshvari M, Behnava B, Miri SM, Elizee PK, Lankarani KB (2010) Peginterferon alpha-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: a single-centre study of 367 cases. Liver Int Off J Int Assoc Study Liver 30:1173–1180
Aslam R, Raza SM, Naeemi H, Mubarak B, Afzal N, Khaliq S (2016) SOCS3 mRNA expression and polymorphisms as pretreatment predictor of response to HCV genotype 3a IFN-based treatment. Springerplus 5:1826
Aziz H, Raza A, Ali K, Khattak JZ, Irfan J, Gill ML (2015) Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy. Int J Infect Dis IJID Off Publ Int Soc Infect Dis 30:91–97
Bahgat NA, Kamal MM, Abdelaziz AO, Mohye MA, Shousha HI, Ahmed MM, Elbaz TM, Nabil NM (2015) Interferon-gamma and interleukin-10 gene polymorphisms are not predictors of chronic hepatitis C (genotype-4) disease progression. Asian Pac J Cancer Prev APJCP 16:5025–5030
Bouzgarrou N, Hassen E, Farhat K, Bahri O, Gabbouj S, Maamouri N, Ben Mami N, Saffar H, Trabelsi A, Triki H, Chouchane L (2009) Combined analysis of interferon-gamma and interleukin-10 gene polymorphisms and chronic hepatitis C severity. Hum Immunol 70:230–236
da Silva Conde SR, Soares Monteiro JC, Silva Dos Santos BT, Fonseca Filgueiras NK, de Almeida Lins PA, Bonfim Freitas F, da Silva Graca E, Demachki S, Ferreira de Araujo MT, Ishak R, Rosario Vallinoto AC (2014) SNP rs8099917 in gene IL28B might be associated with risk of chronic infection by HCV but not with response to treatment. Biomed Res Int 2014:748606
da Silva NM, Germano FN, Vidales-Braz BM, Carmo Zanella R, dos Santos DM, Lobato R, de Martinez AM (2015) Polymorphisms of IL-10 gene in patients infected with HCV under antiviral treatment in southern Brazil. Cytokine 73:253–257
Derbala M, Rizk NM, Al-Kaabi S, John A, Sharma M, El-dweik N, Yakoob R, Pasic F, Almohanadi M, Alejji K, Abdelmola A, Butt M (2013) The predictive value of IL28B rs12979860, rs11881222 and rs8099917 polymorphisms and IP-10 in the therapeutic response of Egyptian genotype 4 patients. Virology 444:292–300
Dzekova-Vidimliski P, Nikolov IG, Matevska-Geshkovska N, Boyanova Y, Nikolova N, Romanciuc G, Dumitrascu D, Caloska-Ivanova V, Joksimovic N, Antonov K, Mateva L, Rostaing L, Dimovski A, Sikole A (2015) Genetic predictors of the response to the treatment of hepatitis C virus infection. Bosn J Basic Med Sci 15:55–59
El-Karaksy HM, Sharaf SA, Mandour IA, Mogahed EA, Rady NH, El-Mougy FA (2016) Effect of interleukin-10 gene promoter polymorphisms-1082 G/A and -592 C/A on response to therapy in children and adolescents with chronic hepatitis C virus infection. Hum Immunol 77:1248–1253
Ezzikouri S, Alaoui R, Rebbani K, Brahim I, Fakhir FZ, Nadir S, Diepolder H, Khakoo SI, Thursz M, Benjelloun S (2013) Genetic variation in the interleukin-28B gene is associated with spontaneous clearance and progression of hepatitis C virus in Moroccan patients. PLoS One 8:e54793
Goossens N, Negro F (2014) Is genotype 3 of the hepatitis C virus the new villain? Hepatology 59:2403–2412
Guo P, Li G, Sun X, Wu D (2016) Influence of IL10 Gene polymorphisms on the sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy. Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis 45:48–55
Haj-Sheykholeslami A, Keshvari M, Sharafi H, Pouryasin A, Hemmati K, Mohammadzadehparjikolaei F (2015) Interferon-lambda polymorphisms and response to pegylated interferon in Iranian hepatitis C patients. World J Gastroenterol 21:8935–8942
Hashmi AH, Ahmad N, Riaz S, Ali L, Siddiqi S, Khan KM, Shakoori AR, Mansoor A (2014) Genotype CC of rs12979860 is providing protection against infection rather than assisting in treatment response for HCV genotype 3a infection. Genes Immun 15:430–432
Hayes CN, Imamura M, Aikata H, Chayama K (2012) Genetics of IL28B and HCV-response to infection and treatment. Nat Rev Gastroenterol Hepatol 9:406–417
Helal SF, Gomaa HE, Thabet EH, Younan MA, Helmy NA (2014) Impact of IL-10 (-1082) promoter-single nucleotide polymorphism on the outcome of hepatitis C virus genotype 4 infection. Clin Med Insights Gastroenterol 7:19–24
Idrees M (2008) Development of an improved genotyping assay for the detection of hepatitis C virus genotypes and subtypes in Pakistan. J Virol Methods 150:50–56
Imran M, Manzoor S, Ashraf J, Khalid M, Tariq M, Khaliq HM, Azam S (2013) Role of viral and host factors in interferon based therapy of hepatitis C virus infection. Virol J 10:299
Imran M, Manzoor S, Azam S, Resham S (2015) Genetic variant of IL28B rs12979860, as predictive marker of interferon-based therapy in Pakistani population. APMIS Acta Pathol Microbiol Immunol Scand 123:342–349
Jablonowska E, Piekarska A, Koslinska-Berkan E, Omulecka A, Szymanska B, Wojcik K (2012) Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin. Acta Biochim Pol 59:333–337
Kaczor MP, Seczynska M, Szczeklik W, Sanak M (2015) IL28B polymorphism (rs12979860) associated with clearance of HCV infection in Poland: systematic review of its prevalence in chronic hepatitis C patients and general population frequency. Pharmacol Rep PR 67:260–266
Khubaib B, Saleem S, Idrees M, Afzal S, Wasim M (2015) The genotype CC of IL-28B SNP rs12979860 is significantly associated with a sustained virological response in chronic HCV-infected Pakistani patients. J Dig Dis 16:293–298
Marcellin P, Cheinquer H, Curescu M, Dusheiko GM, Ferenci P, Horban A, Jensen D, Lengyel G, Mangia A, Ouzan D, Puoti M, Rodriguez-Torres M, Shiffman ML, Schmitz M, Tatsch F, Rizzetto M (2012) High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology 56:2039–2050
Par A, Par G, Tornai I, Szalay F, Varszegi D, Frater E, Papp M, Lengyel G, Feher J, Varga M, Gervain J, Schuller J, Nemes Z, Peterfi Z, Tusnadi A, Hunyady B, Haragh A, Szinku Z, Vincze A, Szereday L, Kisfali P, Melegh B (2014) IL28B and IL10R -1087 polymorphisms are protective for chronic genotype 1 HCV infection and predictors of response to interferon-based therapy in an East-Central European cohort. BMC Res Notes 7:12
Ramos JA, Silva R, Hoffmann L, Ramos AL, Cabello PH, Urmenyi TP, Villella-Nogueira CA, Lewis-Ximenez L, Rondinelli E (2012) Association of IL-10, IL-4, and IL-28B gene polymorphisms with spontaneous clearance of hepatitis C virus in a population from Rio de Janeiro. BMC Res Notes 5:508
Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour JF, Furrer H, Gunthard HF, Heim M, Hirschel B, Malinverni R, Moradpour D, Mullhaupt B, Witteck A, Beckmann JS, Berg T, Bergmann S, Negro F, Telenti A, Bochud PY, Swiss Hepatitis CCS, Swiss HIVCS (2010) Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138:1338–1345 (1345 e1331–1337)
Rizk HH, Hamdy NM, Al-Ansari NL, El-Mesallamy HO (2016) Pretreatment predictors of response to PegIFN-RBV therapy in Egyptian patients with HCV genotype 4. PLoS One 11:e0153895
Sepahi S, Pasdar A, Ahadi M, Gerayli S, Rostami S, Meshkat Z (2014) Haplotype analysis of interleukin-10 gene promoter polymorphisms in chronic hepatitis C infection: a case–control study. Viral Immunol 27:398–403
Sghaier I, Mouelhi L, Rabia NA, Alsaleh BR, Ghazoueni E, Almawi WY, Loueslati BY (2017) Genetic variants in IL-6 and IL-10 genes and susceptibility to hepatocellular carcinoma in HCV infected patients. Cytokine 89:62–67
Shaikh N, Waryah AM, Devrajani BR, Rajput MI, Hayat AS, Shaikh S (2015) IL28B rs12980275 polymorphism shows association with response to treatment in Pakistani patients with chronic hepatitis C. J Med Virol 87:814–820
Shaker OG, Sadik NA (2012) Polymorphisms in interleukin-10 and interleukin-28B genes in Egyptian patients with chronic hepatitis C virus genotype 4 and their effect on the response to pegylated interferon/ribavirin-therapy. J Gastroenterol Hepatol 27:1842–1849
Shaker OG, Abdel-Rahim MT, Bayoumi ST (2015) Gene polymorphisms of IL-10 and MxA in responders and non-responders to interferon therapy in HCV Egyptian patients genotype 4. Cell Biochem Biophys 71:617–625
Swiatek-Koscielna B, Kaluzna E, Strauss E, Januszkiewicz-Lewandowska D, Bereszynska I, Wysocki J, Rembowska J, Barcinska D, Antosik D, Mozer-Lisewska I, Nowak J (2017) Interleukin 10 gene single nucleotide polymorphisms in Polish patients with chronic hepatitis C: analysis of association with severity of disease and treatment outcome. Hum Immunol 78:192–200
Thrift AP, El-Serag HB, Kanwal F (2017) Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol 14:122–132
Uemura H, Uchida Y, Kouyama JI, Naiki K, Yamaba S, Fuchigami A, Saito Y, Shiokawa K, Fujii Y, Uchiya H, Nakazawa M, Ando S, Nakao M, Motoya D, Sugawara K, Inao M, Imai Y, Nakayama N, Tomiya T, Mochida S (2017) Retreatment with sofosbuvir/ledipasvir with or without lead-in interferon-β injections in patients infected with genotype 1b hepatitis C virus after unsuccessful daclatasvir/asunaprevir therapy. Hepatol Res. https://doi.org/10.1111/hepr.12980
Umer M, Iqbal M (2016) Hepatitis C virus prevalence and genotype distribution in Pakistan: comprehensive review of recent data. World J Gastroenterol 22:1684–1700
Acknowledgements
We are grateful to all the hospital and laboratory staff, and patients who participated in this study.
Funding
The research was supported by Higher Education Commission Pakistan start-up research grant (PM-IPFP/HRD/HEC/2011/2257).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors declare no conflict of interest.
Ethical approval
The research was approved by the Institutional ethical and the review committee accordingly to the Helsinki Declaration and its later amendments.
Informed consent
Informed consents were taken from all the subjects i.e., Patients and healthy controls before start of sample collection.
Additional information
Handling Editor: Michael A. Purdy.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Naeemi, H., Aslam, R., Raza, S.M. et al. Distribution of IL28B and IL10 polymorphisms as genetic predictors of treatment response in Pakistani HCV genotype 3 patients. Arch Virol 163, 997–1008 (2018). https://doi.org/10.1007/s00705-018-3711-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00705-018-3711-3